A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Active, not recruiting · Phase 1 · NCT06291220
Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
At a glance
- Research payments reported, 2025
- $228,299
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 4
About the trial
- Sponsor
- AbbVie
- Tested
- Obinutuzumab (drug), ABBV-453 (drug)
- Dates
- Started 2025-01-27; completion 2027-07
- Results posted
- Not yet
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries. The purpose of this study is to assess how well ABBV-453 works adult participants with relapsed/refractory (R/R) untreated CLL/small lymphocytic lymphoma (SLL). Adverse events, pharmacokinetics, and change in disease activity will be assessed. ABBV-453 is an investigational drug for the treatment of CLL and SLL. Participants will be enrolled with a specific target dose and receive obinutuzumab during the debulking period followed escalating doses of ABBV-453, until the appropriate target dose is achieved. Approximately 60 adult participants with previously R/R CLL/SLL will be enrolled in the study in appr…
From ClinicalTrials.gov, last updated 2026-09-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $228,299 in research payments for this study in 2025 (13 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Thomas J. Kipps, M.D. Internal Medicine · La Jolla, CA
- Tanya Siddiqi, M.D. Hematology · Duarte, CA
- Patrick W. Cobb, M.D. Hematology & Oncology · Billings, MT
- Danielle M. Brander, M.D. Hematology & Oncology · Durham, NC
- Ryan W. Jacobs, MD Hematology · Charlotte, NC
- Stephen E. Spurgeon, MD Internal Medicine · Portland, OR
- William G. Wierda, M.D., PHD Hematology & Oncology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Ut MD Anderson Cancer Center $79,235
- Regents of the Univ of California $51,604
- Ohsu Hospital and Clinics, OR $40,900
- Duke University $22,788
- City of Hope National Medical Ctr $19,349
- Wake Forest University $11,726
- Intermountain Health St Vincent Regional Hospital, MT $2,698
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.